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Abstract
Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous male malignancy 
and one of the leading causes of cancer-related mortality in the United States. Biologic 
heterogeneity of PCa results is different presentations ranging from indolent to highly 
aggressive tumors with high morbidity and mortality. Due to this broad range of clini-
cal behavior, it is required to differentiate clinically significant PCa (csPCa) tumors and 
reduce detection of indolent cancers. PCa is generally diagnosed with non-targeted sys-
tematic trans-rectal ultrasound (TRUS)-guided biopsy in patients with elevated prostate 
serum antigen (PSA) or abnormal digital rectal examination (DRE). Non-targeted sys-
tematic TRUS as the typical imaging modality for assessing the prostate, samples only a 
small part of the gland with a high possibly that the biopsy results may not catch the most 
aggressive tumor in the gland accurately. Multi-parametric (MP) magnetic resonance 
imaging (MRI), as the most specific and sensitive imaging modality in PCa management, 
has been reported to be the reference standard for prostate imaging endorsed. However, 
there are a variety of interpretive pitfalls, which have been reported to be encountered at 
mpMRI of the prostate. The purpose of this chapter is to provide a summary of the cur-
rent advances in accurate detection of PCa.
Keywords: prostate cancer (PCa), prostate specific antigen, digital rectal exam, trans-rectal 
ultrasound guided biopsy (TRUSgBX), Gleason scores, multi-parametric (MP) magnetic 
resonance imaging (MRI)
1. Introduction
Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous male malignancy and 
one of the leading causes of cancer-related mortality in the United States [1–3]. PCa is a disease 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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of increasing significance in the world. Even though PCa may be less common in many devel-
oping countries, but its incidence and mortality rate has been raised [4]. The incidence of PCa 
influenced by the diagnostic efforts and the mortalities reported for any specific geographic 
region depending on the reliability of cancer detected [5]. The range of the five-year survival 
rate varies from 29% in patients with metastatic PCa to 100% in patients with localized disease 
[6, 7]. Biologic heterogeneity of PCa results is different presentations ranging from indolent 
to highly aggressive tumors with high morbidity and mortality [8] that affects the therapy, 
response, and prognosis of patients with PCa. Due to this broad range of clinical behavior, 
it is required to differentiate clinically significant prostate cancers (csPCa) tumors, defined 
as presence of Gleason pattern >4 and/or tumor volume > 0.5 ccs, and reduce detection of 
indolent cancers [9], since candidates for therapy from clinically insignificant tumors that can 
undergo active surveillance without any harm. Traditional treatment of PCa varies from radi-
cal prostatectomy (RP) or radiotherapy (RT) to watchful waiting [10, 11]. When prostate spe-
cific antigen (PSA) tests became beneficial for PCa screening, the United States gained a huge 
increase in the incidence of the disease [12]. Several years ago, many PCa were detected dur-
ing the pathological exam of specimens from trans-urethral prostatectomies. These patients 
underwent surgery for benign prostatic hyperplasia (BPH), but up to 25% were found to have 
malignancy [13, 14]. However, the frequency of detecting such incidental cancers has gone 
down since PSA came into existence, as most of the men undergoing surgery for BPH have 
their PSA tested.
PCa is generally diagnosed with non-targeted systematic trans-rectal ultrasound (TRUS)-
guided biopsy in patients with elevated PSA or abnormal digital rectal examination (DRE).
2. Prostate cancer diagnosis
2.1. Prostate specific antigen (PSA)
PSA is a natural enzyme that is produced entirely by the prostatic epithelial cells and is used 
as a marker for PCa. However, PSA is not cancer-specific as BPH, prostatitis and other urinary 
symptoms may elevate PSA levels. There is no absolute PSA level which indicates PCa and 
there is no PSA level below, which a man is assured not to have PCa, although higher PSA 
is associated with risk of PCa [15]. Traditionally, a level ≥ 4 ng/ml has been well-known as 
suspicious of PCa that indicated the need for biopsies. However, at this level, only about 30% 
of men with elevated levels will have PCA and normal levels may falsely exclude the presence 
of PCa, suggesting that PSA should not be used to exclude or diagnose PCa [16–20].
2.2. Digital rectal exam (DRE)
DRE is an essential part of the clinical exam of the patient when a tumor is palpable. Over 
70% of lesions are located in the peripheral zone (PZ) and are palpable when they are bigger 
than a certain size [21]. Twenty-five percent of the tumors are located in the transitional zone 
(TZ) and cannot be reachable by DRE because of their location. Other than that as PCa is now 
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detected at smaller tumor volumes and earlier stages, the number of palpable tumors is sig-
nificantly reduced. This decreases sensitivity and specificity of the DRE [22–25]. Suspicious 
outcomes at DRE are an indicator of more aggressive PCa [26, 27] and trigger the need for 
prostate biopsies [27].
2.3. TRUS and TRUS guided biopsy (TRUSgBX)
TRUS is the typical imaging modality for assessing the prostate. Histological examination 
of 10–12 TRUSgBX cores from standard zones in the prostate is a gold standard for diagno-
sis of PCa [28]. Prostate biopsies have played a role from pure cancer detection to clinical 
management in the past several years. TRUS is typically the best way for measuring the 
volume of the prostate gland as well as guiding the biopsy needle; however, it lacks in both 
specificity and sensitivity for detection of PCa [28, 29]. Most of the lesions appear hypo-
echoic compared to the normal PZ; but some lesions are barely visible since about half of 
the cancer lesions are iso-echoic [29, 30] and cannot be detected. In addition, evaluation of 
the TZ on TRUS is limited because of the heterogeneity in the appearance caused by BPH 
making it difficult to detect especially the tumors located anteriorly. Thus, there is a con-
siderable risk that a tumor is either being missed or the aggressive part of the tumor is not 
picked by the systematic biopsies. This may result in either repeated biopsies or incorrect 
Gleason score (GS).
TRUS guided prostate biopsy samples only a small part of the gland with a high possibility 
that the biopsy results may not catch the most aggressive tumor in the gland accurately [31, 32]. 
Non-targeted TRUSgBX usually takes 6–12 core biopsies of the PZ, which harbors about 70% 
of PCa [33]. The limitations of non-targeted TRUSgBX are well discussed in the recent year 
studies [34] with over 20% of false negative rate [35–37]. Also, non-targeted TRUSgBX may 
not provide accurate information about the volume and aggressiveness of PCa. It’s been 
reported in some recent studies that after RP, 30–45% of the patients are upstaged from their 
initial diagnosis at TRUSgBX [38]. The anterior gland, TZ, and apex of the gland, which are 
recognized as areas with high possibilities of containing csPCa, are known to be under/not-
sampled at standard TRUSgBX [39]. Since treatment protocol is completely based on risk 
stratification and depend on accurate GS, these limitations are very critical. It also leads to over-
diagnosis of indolent PCa, which provides no benefit to the patients, and under-diagnoses 
of clinically significant tumors, which potentially harms patients. It has been reported that 
approximately 60% of patients with a diagnosis of indolent tumor choose aggressive treat-
ment options such as RP, leading to numerous complications [40, 41]. The biopsies can also 
result in complications including bleeding and infections [42, 43]. Endoscopic ultrasound-
guided fine needle aspiration (EUS-FNA) biopsy requires sedation and is associated with sig-
nificant risks of complications such as pancreatitis, bowel perforation, and aspiration, which 
can be fatal [44]. In addition, confounding issue with needle biopsy is that most of the tumor 
mass is made up of stromal cells, not the epithelial cancer cells. Despite being the gold stan-
dard, EUS-FNA only has a sensitivity of 75–94% and a specificity of 78–95% [45]. The current 
diagnostic paradigm for PCa diagnosis has low diagnostic accuracy when they are associated 
with significant risk and cost [46].
Advances in Medical Imaging Technology for Accurate Detection of Prostate Cancer
http://dx.doi.org/10.5772/intechopen.77327
19
3. Gleason scores (GS) for grading PCa
The histopathological aggressiveness of PCa is graded by the GS [47, 48]. The cancer tissue 
is graded on a scale from 1 to 5 based on the appearance of the cancerous cells and histo-
pathological arrangement. This discrepancy between cancer and normal tissue reflects the 
aggressiveness of cancer. Since more than one class of Gleason grade is usually present in the 
biopsy tissue, a combination GS (ranging from 2 to 10) combining the dominant and the high-
est grade is assigned. The GS is intensely correlated to the clinical characteristics of the tumor 
and is a potent prognostic factor for treatment response. High GS indicates increased tumor 
aggressiveness and increased risk of tumor spread with a worse prognosis [49–52]. Hence, 
it has been suggested to divide the GS into risk groups based on the risk of metastasis and 
progression [53]. The risk assessment of a patient with diagnosed PCa and the treatment plan 
is highly based on the GS from TRUSgBX, which can be inaccurate because of sampling error, 
considering that the GS is upgraded in about 30% of the patient after RP [54]. Incorrect biopsy 
reported GS can result in incorrect risk stratification and possible under or over-treatment. 
The change of the reported GS during the past years with broadening of the Gleason grade 4 
criteria [55] to improve the correlation between biopsy and RP GSs has resulted in a signifi-
cant upgrade of tumor GS and made it difficult to compare pathological data over time. GS, 
as one of the best indicators of PCa, is a strong determinant of treatment selection. RP GS is an 
established prognostic indicator for recurrence of the disease. Therefore, accurate prediction 
of the final RP GS is critical. Clinical staging of PCa is based on the TNM classification [55, 56].
4. Magnetic resonance imaging (MRI) of the prostate
MRI of the prostate is performed on 1.5–3.0 Tesla MRI scanners combined with a pelvic 
phased-array coil placed over the pelvis with or without an endorectal coil (ERC) depend-
ing on the clinical situation. ERC, which is placed in the rectum just posterior to the prostate 
gland, reduces motion artifacts, and enhances image quality; but it has some disadvantages 
including increased scan time, increased costs, and reduced patient compliance because of 
the location of the coil in the rectum. The majority of prostatic MRI examinations can be 
performed with acceptable image quality without an ERC because of the increased spatial 
resolution (the ability to separate two dense structures from each other) and the increased 
signal-to-noise ratio on 3.0 T MRI. However, several studies reported improved image quality 
and diagnostic performance with an ERC [57, 58]. The European society of urogenital radiol-
ogy’s (ESUR) MR prostate guidelines states that the use of an ERC is optional for detection 
and preferable for staging at 3.0 T MRI [59].
4.1. Multi-parametric MRI (mpMRI)
Multi-parametric (MP) MRI, as the most specific and sensitive imaging modality in PCa man-
agement, has been reported to be the reference standard for prostate imaging endorsed [60, 61]. 
While TRUSgBX evaluates a limited piece of the prostate gland, magnetic resonance (MR) 
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images  provide detailed information about the whole prostate gland and potentially may 
be more accurate than random TRUSgBX [62]. The development of mp-MRI provides new 
possibilities in detection, characterization of the lesson and staging of PCa due to its high 
resolution and soft-tissue contrast [62]. Recently published data [62–67] indicates the rap-
idly growing use of mpMRI as the most specific and sensitive diagnostic imaging modal-
ity for PCa management. MpMRI provides detailed information about the morphological, 
metabolic, and cellular changes in the prostate as well as characterize tissue vascularity and 
correlate it to tumor aggressiveness [68, 69]. MP MRI sequences include high-resolution ana-
tomical T2-weighted (T2W) and T1-weighted (T1W) images in combination with one or more 
functional MRI techniques such as diffusion-weighted imaging (DWI) and dynamic contrast-
enhanced (DCE) imaging [63]. Two recently reported meta-analyses revealed that mpMRI 
has a high negative predictive value (NPV) for the detection of csPCa [70, 71], and it has been 
shown that mpMRI can estimate grade of PCa compared to histopathology results with a high 
degree of accuracy [72, 73]. Being noninvasive, a pathway with mpMRI as a predicting test in 
order to determine, which men with an elevated PSA undergo biopsy might reduce unneces-
sary biopsies, which are the pitfalls of routine screening practice and improve detection and 
diagnostic accuracy.
4.2. Multi-parametric MRI (mpMRI) pitfalls
There are several interpretive pitfalls, which have been reported [74] to be encountered at 
mpMRI of the prostate: Normal anatomic structures can mimic anterior and TZ located 
lesions; post-biopsy hemorrhage can mimic PZ PCa on T2W MRI; BPH resembles TZ PCa; 
acute and chronic prostatitis mimics PCa; ductal variant adenocarcinoma may be occult on 
T2W MRI. Moreover, technical pitfalls may be encountered at MP-MRI of the prostate: T2W 
motion correction with radial acquisition obscures some PCa; visual/quantitative analysis of 
DWI for tumor detection/grading is complex; DCE lacks standardization and is limited in the 
TZ; targeted biopsy of MR-detected lesions using TRUS-guidance is challenging. A failure 
to recognize and correct these types of errors may result in suboptimal care. False positive 
diagnoses of areas of potential cancers at mpMRI generate clinical uncertainty and often lead 
to multiple pointless biopsies or in certain cases surgical management of low-grade disease. 
Failure to recognize clinically significant cancers in males could result in suboptimal patient 
outcomes [74].
4.3. Accuracy of mpMRI
A study by Borofsky et al. [75] showed that of the 162 lesions, 136 (84%) were correctly identi-
fied with mpMRI and 16% were missed. In their study, among the lesions missed at mpMRI, 
GS was 3 + 4 in 17 (65%), 4 + 3 in one (4%), 4 + 4 in seven (27%), and 4 + 5 in one (4%). They 
reported that mpMRI has excellent sensitivity in the detection of PCa on an overall patient 
basis; however, a substantial number of cancers are missed either because lesions are not 
apparent or because they are too subtle for detection. Of those missed lesions, 58% were not 
visualized or were characterized as benign findings even at the second-look evaluation. They 
conclude that clinically important lesions can be missed, or their size can be underestimated 
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at mpMRI [75]. Some previous studies also showed that in some cases tumors were invisible 
including lesions with pathologic GS greater than 3 + 4 and pathologic volume of more than 
0.5 mL [75, 76]. The subset of missed lesions that could not be seen despite focused search on 
second look suggests that truly invisible lesions do exist.
A recent meta-analysis of seven studies including 526 patients showed a pooled sensitivity of 
74% for mpMRI in the detection of clinically important cancers [77]. When compared with the 
current paradigm of PSA measurement and TRUSgBX, the introduction of mpMRI is clearly 
an improvement. It has recently been demonstrated in a prior cohort study by Ahmed et al. 
[78], that using mpMRI, allows 27% of patients to avoid a primary biopsy and diagnosis of 
5% fewer clinically non-csPCa; and if subsequent TRUSgBX were directed by mpMRI find-
ings, more cases of csPCa might be detected compare to the standard pathway of TRUSgBX 
for all [78]. This approach could potentially save a quarter of the population from the cost and 
complications of TRUSgBX. Rosenkrantz et al. [79] showed that mpMRI had a sensitivity of 
76% when compared with matched pathology specimens. Similar studies by Le et al. [80] and 
Russo et al. [81] using pathology results as the reference standard showed 80–90% sensitivity. 
However, they found that 30% of tumors with a GS > 7 and larger than 1.0 cm were missed at 
MR imaging [80]. De Visschere et al. [82] reported that the majority of missed lesions were low 
grade and confined to the organ. A retrospective review of mpMRI in patients with missed 
lesions in their study revealed that the majority of missed lesions had a lower score, and PCa 
was multifocal in these patients. A paired analysis in patients in whom prospective read-
ing missed lesions revealed that missed lesions were two to three times smaller in volume 
(0.86 mL vs. 2.13 mL, P = 0.001), which can be possibly explained by limitations associated 
with spatial resolution of MR imaging. [75, 82]
5. Conclusion
In conclusion, mpMRI has become an important factor for patients being enrolled in 
active surveillance protocols for the management of low-grade PCa. mpMRI is a proven 
imaging modality that can accurately detect csPCa. Several pitfalls, both interpretive and 
technical, may be encountered at mpMRI of the prostate, and a failure to recognize these 
pitfalls can lead to suboptimal patient care. Targeted biopsies of mpMRI detected lesions 
pose a challenge in clinical practice. The limitations of TRUSgBX should be acknowledged 
in order to improve the diagnostic accuracy of targeted biopsies and finally a detailed 
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